J&J press­es pause on a part­ner's PhI prostate can­cer study, cut­ting off po­ten­tial Er­lea­da com­bo

J&J has de­cid­ed to hit the brakes on one of its part­ner’s ear­ly-stage pro­grams.

The Big Phar­ma’s Janssen di­vi­sion will halt en­roll­ment in ES­SA Phar­ma’s Phase I tri­al for a prostate can­cer pro­gram, ES­SA an­nounced Mon­day morn­ing, due to what the biotech de­scribed as “op­er­a­tional re­cruit­ment chal­lenges.” An ES­SA spokesper­son told End­points News in an email that it will con­duct a Phase I study us­ing the Janssen drugs on its own, but pos­si­bly in a dif­fer­ent pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER